Involvement of CYP2C9 and UGT2B7 in the metabolism of zaltoprofen, a nonsteroidal anti-inflammatory drug, and its lack of clinically significant CYP inhibition potential

British Journal of Clinical Pharmacology

Volumn 54, Issue 3, 2002, Pages 295-303

  Furuta, Shigeru ^a   Akagawa, Nobuyoshi ^b   Kamada, Emiko ^a   Hiyama, Akio ^b   Kawabata, Yoshihiro ^a   Kowata, Nobuhiko ^b   Inaba, Atsuhiro ^c   Matthews, Anne ^d   Hall, Michael ^d   Kurimoto, Tadashi ^a  

^a ZERIA PHARMACEUTICAL CO LTD   (Japan)

^b Nippon Chemiphar Co Ltd   (Japan)

^c DAIICHI PURE CHEMICALS CO LTD   (Japan)

^d HUNTINGDON LIFE SCIENCES   (United Kingdom)

Author keywords

CYP2C9; Human liver microsomes; in vitro metabolism; UGT2B7; Zaltoprofen

Indexed keywords

ALPHA NAPHTHOFLAVONE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DIETHYLDITHIOCARBAMIC ACID; DRUG METABOLITE; ENZYME INHIBITOR; FURAFYLLINE; GLUCURONOSYLTRANSFERASE; KETOCONAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; QUINIDINE; SULFAPHENAZOLE; TRANYLCYPROMINE; TROLEANDOMYCIN; ZALTOPROFEN;

ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HYDROXYLATION; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARYL HYDROCARBON HYDROXYLASES; BENZOPYRANS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA, COMPLEMENTARY; DRUG INTERACTIONS; GLUCURONOSYLTRANSFERASE; HUMANS; ISOMERISM; MICROSOMES, LIVER; PROPIONIC ACIDS;

EID: 18544377505     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2002.01649.x     Document Type: Article

References (30)

1. Ito A, Mori Y. Effect of a novel anti-inflammatory drug, 2-(10, 11-dihydro-10-oxo-dibenzo [b, f ] -thiepin-2-yl) propionic acid (CN-100), on the proteoglycan biosynthesis in articular chondrocytes and prostaglandin E2 production in synovial fibroblasts. Res Commun Chem Pathol Pharmacol 1990; 70: 131-142.
2. Sasaki K, Iizuka K, Sano H, Miwa M, Haruki S. Pharmacokinetics of CN-100 for 80 mg tablet of final preparation in healthy volunteers. Jpn Pharmacol Ther 1992; 20: 2167-2174.
3. Newton DJ, Wang RW, Lu AYH. Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 1995; 23: 154-158.
4. Baldwin SJ, Bloomer JC, Smith GJ, et al. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 1995; 25: 261-270.
5. Moody GC, Griffin SJ, Mather AN, McGinnity DF, Riley RJ. Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: Assessment of human CYP inhibition potential. Xenobiotica 1999; 29: 53-75.
6. Furuta S, Kamada E, Suzuki T, et al. Inhibition of drug metabolism in human liver microsomes by nizatidine, cimetidine and omeprazole. Xenobiotica 2001; 31: 1-10
7. Taavitsainen P, Juvonen R, Pelkonen O. In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene. Drug Metab Dispos 2001; 29: 217-222
8. Ono S, Hatanaka T, Hotta H, et al. Specificity of substrate and inhibitor probes for cytochrome P450s: Evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica 1996; 26: 681-693
9. Ohyama K, Nakajima M, Suzuki M, et al. Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: Prediction of in vivo drug interactions. Br J Clin Pharmacol 2000; 49: 244-253.
10. Ito K, Iwatsubo T, Kanamitsu S, et al. Prediction of pharmacokinetic alterations caused by drug-drug interactions: Metabolic interaction in the liver. Pharmacol Rev 1998; 50: 387-411.
11. Kohl C, Steinkellner M. Prediction of pharmacokinetic drug/drug interactions fromin vitro data: Interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants. Drug Metab Dispos 2000; 28: 161-168
12. Prakash C, Kamel A, Cui D, et al. Identification of the major human liver cytochrome P450 isoform (s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Br J Clin Pharmacol 2000; 49(Suppl 1): 35S-42S.
13. Jin C, Miners JO, Lillywhite KJ, Mackenzie PI. Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs. J Pharmacol Exp Ther 1993; 264: 475-479.
14. Coffman BL, King CD, Rios GR, Tephly TR. The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y (268) and UGT2B7H (268). Drug Metab Dispos 1998; 26: 73-77.
15. Burke MD, Prough RA, Mayer RT. Characteristics of a microsomal cytochrome P-448-mediated reaction. Ethoxyresorufin O-de-ethylation. Drug Metab Dispos 1977; 5: 1-8.
16. Miners JO, Smith KJ, Robson RA, et al. Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochem Pharmacol 1988; 37: 1137-1144.
17. Chauret N, Gauthier A, Martin J, Nicoll-Griffith DA.In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat, and horse. Drug Metab Dispos 1997; 25: 1130-1136.
18. Kronbach T, Mathys D, Gut J, Catin T, Meyer UA. High-performance liquid chromatographic assays for bufuralol 1′-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Anal Biochem 1987; 162: 24-32.
19. Parker GL, Orton TC. Induction by oxyisobutyrates of hepatic and kidney microsomal cytochrome P-450 with specificity towards hydroxylation of fatty acids. In Biochemistry, Biophysics and Regulation of Cytochrome P-450, eds Gustafsson JÅ, Carlstedt-Duke J, Mode A, Rafter J. Elsevier/North Holland Biomedical Press, Amsterdam, 373-377.
20. Sonderfan AJ, Arlotto MP, Dutton DR, McMillen SK, Parkinson A. Regulation of testosterone hydroxylation by rat liver microsomal cytochrome P-450. Arch Biochem Biophys 1987; 255: 27-41.
21. Sano H, Segawa Y, Furuta S, et al. Drug interaction of zaltoprofen, a novel anti-inflammatory drug, and its effect on hepatic drug metabolizing enzyme. Jpn Pharmacol Ther 1995; 23: 1477-1487.
22. Haruki S, Yamada A. Absorption, distribution, metabolism and excretion of CN-100, (±) -2-(10, 11-dihydro-10-oxodibenzo[b, f ]thiepin-2-yl) propionic acid in rats. Jpn Pharmacol Ther 1990; 18: 3843-3863.
23. Carlile DJ, Hakooz N, Bayliss MK, Houston JB. Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans. Br J Clin Pharmacol 1999; 47: 625-635.
24. Miners JO, Birkett DJ. Cytochrome P4502C9 is an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45: 525-538.
25. Martin JH, Begg EJ, Kennedy MA, Roberts R, Barclay ML. Is cytochrome P450 2C9 genotype associated with NSAID gastric ulceration? Br J Clin Pharmacol 2001; 51: 627-630
26. 359 variants: Enzyme kinetic study with seven substrates. Pharmacogenetics 2000; 10: 95-104.
27. Hodgson E, Levi PE. Species, organ and cellular variation in the flavin-containing monooxygenase. Drug Metabol Drug Interact 1988; 6: 219-233.
28. He M, Rettie AE, Neal J, Trager WF. Metabolism of sulfinpyrazone sulfide and sulfinpyrazone by human liver microsomes and cDNA-expressed cytochrome P450s. Drug Metab Dispos 2001; 29: 701-711.
29. Tang C, Shou M, Rushmore TH, et al. In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: Correlation with CYP2C9 genotype and in-vivo pharmacokinetics. Pharmacogenetics 2001; 11: 223-235
30. Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 1999; 27: 1350-1359.